Journal de Mycologie Médicale

Journal de Mycologie Médicale, known in English as Journal of Medical Mycology, is the official journal of the French Society for Medical Mycology (Société Française de Mycologie Médicale, SFMM), published by Elsevier Masson SAS, founded in 1991, issued four times a year, with a 2025 Journal Impact Factor of 2.4 and a CiteScore of 4.5.《医学真菌学杂志》是法国医学真菌学会（Société Française de Mycologie Médicale，SFMM）的官方期刊，由 Elsevier Masson SAS 出版，1991 年创刊，每年出版 4 期，英文题名亦作 Journal of Medical Mycology，2025 年期刊影响因子为 2.4，CiteScore 为 4.5。

Scope

• Human and animal mycology defines the remit, and the aims page states that contributions appear in English and must be clear, precise and concise.范围是人类与动物的真菌学，宗旨页说明稿件以英文发表，并须写得清晰、准确而简洁。
• Clinical aspects of mycoses are named first in the aims, which places the patient-side picture of fungal infection alongside the laboratory work that supports it.真菌病的临床方面在宗旨中列于首位，患者的临床表现与支持诊疗的实验室工作被放在同一条线上。
• Diagnosis is a subject in its own right, from the laboratory identification of the causative organism to the reading of a result against the clinical picture.诊断作为独立方向处理，从病原体的实验室鉴定，到结合临床表现判读检验结果。
• Epidemiological work tracks where and among whom mycoses occur, including the geographical distribution of a species and the surveillance that records changes in it.流行病学方向追踪真菌病发生的地点与人群，包括物种的地理分布以及记录其变化的监测工作。
• Immunological aspects cover the host response to fungal infection, and immunochemistry sits with them among the basic disciplines that the journal lists.免疫学方面涉及宿主对真菌感染的反应，免疫化学与它一同列在刊物给出的基础学科清单中。
• Pathological aspects concern the tissue changes that infection produces and the histological evidence on which a diagnosis of mycosis rests.病理学方面关注感染造成的组织改变，以及真菌病诊断所依据的组织学证据。
• Preventive aspects take in the measures that keep infection from arising, a subject that carries particular weight in hospitals and among immunocompromised patients.预防方面涵盖阻止感染发生的各项措施，这一主题在医院与免疫功能低下的患者中分量尤重。
• Therapeutic aspects cover antifungal treatment and the clinical decisions that surround it, and they connect to the diagnostic and preventive subjects rather than standing apart.治疗方面涵盖抗真菌治疗及其周边的临床决策，与诊断、预防两个方向相互衔接。
• Basic work linked to morphology has a place, with electron and photonic microscopy named on the aims page as tools for describing pathogenic and opportunistic fungi.与形态学相关的基础研究占有一席之地，宗旨页把电子显微镜与光学显微镜并列为描述病原真菌与机会性真菌的工具。
• Physiology and biochemistry are listed as basic subjects, in the same group as cellular and molecular biology and as immunochemistry.生理学与生物化学被列为基础方向，与细胞生物学、分子生物学以及免疫化学同在一组。
• Cellular and molecular biology and genetics complete that group, and they give the journal a laboratory-science core alongside its clinical content.细胞与分子生物学以及遗传学补全了这一组，使刊物在临床内容之外保有实验室科学的根基。
• Taxonomy and phylogeny of pathogenic or opportunistic fungi are explicitly in scope, so the description of a new species is a subject the journal can carry.病原真菌与机会性真菌的分类学与系统发育学明确在范围内，新种的描述因此是刊物可以承载的主题。
• Actinomycetes appear beside fungi throughout the aims, so the organismal remit reaches beyond the fungal kingdom itself.放线菌在宗旨中始终与真菌并列，刊物的对象范围因此超出真菌界本身。
• Natural-product work faces one condition, since the aims accept it only with chemical characterization and identification of the compounds responsible for the antifungal activity.天然产物研究另有一条门槛，宗旨要求必须完成化学成分表征，并鉴定出产生抗真菌活性的化合物，否则不予考虑。
• Case reports follow a similar rule, and only clinical cases with real originality, a new species, a new clinical presentation or a new geographical localization, together with full documentation, are considered.病例报告遵循同样的规则，只有具备真正原创性且资料完整的临床病例才会被考虑，原创性可以是新种、新的临床表现或新的地理分布。
• Article types run from guest editorials, original articles and reviews, including minireviews, to case reports, technical notes, letters to the editor and information items.稿件类型从客座社论、原创论文与综述（含小型综述），到病例报告、技术札记、致编辑信与信息类文章。

History

• The French Society for Medical Mycology founded the title in 1991, and the first volume carries that year, a date the National Library of Medicine also records as the first year of publication.法国医学真菌学会于 1991 年创办该刊，第 1 卷即标注这一年，美国国家医学图书馆也把 1991 年记为首年。
• The 1991 imprint names Masson of Paris, and that name survives in Elsevier Masson SAS, the publisher printed in the current copyright line.1991 年的出版记录署名巴黎的 Masson，这个名字保留在 Elsevier Masson SAS 之中，后者正是现行版权行里的出版方。
• The copyright line reads Copyright 2026 SFMM, published by Elsevier Masson SAS, so the society keeps ownership of the title while production and distribution sit with the publisher.版权行写作 Copyright 2026 SFMM，出版方为 Elsevier Masson SAS，学会保留刊物所有权，生产与发行由出版方承担。
• Volume numbering has run without a break, with volume 30 in 2020, volume 35 in 2025 and volume 36 in 2026, one volume for each calendar year.卷号连续未断，2020 年为第 30 卷，2025 年为第 35 卷，2026 年为第 36 卷，每个日历年一卷。
• Four issues make a volume, the quarterly rhythm that both the library record and the publisher's issue list confirm, and the latest issue is dated December 2026.每卷 4 期，这一季刊节奏得到图书馆记录与出版社期号表的双重印证，最新一期标注 2026 年 12 月。
• MEDLINE and PubMed have covered the journal from volume 22, issue 1, in March 2012, and the Science Citation Index Expanded also indexes the title.MEDLINE 与 PubMed 自 2012 年 3 月第 22 卷第 1 期起收录该刊，Science Citation Index Expanded 同样收录。
• Impact factors over four years read 3.746 for 2022, 2.2 for 2023, 1.8 for 2024 and 2.4 for 2025, with a five-year figure of 2.3.近四年的影响因子分别为 2022 年 3.746、2023 年 2.2、2024 年 1.8 与 2025 年 2.4，五年影响因子为 2.3。
• CiteScore from Scopus stands at 4.5, and the Journal Citation Reports place the title in mycology at rank 22 of 33, a Q3 position in the Science Citation Index Expanded edition.Scopus 的 CiteScore 为 4.5，期刊引证报告把该刊归入真菌学类目，33 种期刊中排第 22，在 Science Citation Index Expanded 版次中处于 Q3。
• Output runs at about 36 articles a year, total citations reach 1655, and a cited half-life of 6.5 years points to a literature that is replaced slowly.年发文约 36 篇，总被引 1655 次，被引半衰期 6.5 年，说明文献更替较慢。
• The publisher reports 187 days from submission to acceptance, 2 days from acceptance to online publication and an acceptance rate of 24 per cent.出版社公布的数据为投稿到接收 187 天、接收到在线发表 2 天，接收率 24%。
• Subscription and gold open access run side by side, gold articles account for 17.24 per cent of the content, and the author guidelines state that the journal has no page charges.订阅与金色开放获取两条路线并行，金色文章占 17.24%，作者指南写明该刊不收版面费。
• Indexing reaches the main international databases, and the full text is served worldwide through ScienceDirect and ClinicalKey.收录覆盖主要国际数据库，全文经 ScienceDirect 与 ClinicalKey 向全球提供。

Editors

• Three editors-in-chief share the post, and Alix Coste, who heads the list, works at the Institute of Microbiology of the Lausanne University Hospital in Switzerland.主编一职由三位学者共同担任，其中（Alix Coste）任职于瑞士洛桑大学医院的微生物研究所。
• Christophe Hennequin works in the department of parasitology and mycology at Hospital Saint-Antoine in Paris, while Christine Imbert comes from the Laboratory of Ecological and Biological Interactions in Poitiers.（Christophe Hennequin）在巴黎的 Hospital Saint-Antoine 寄生虫学与真菌学系工作，（Christine Imbert）则来自普瓦捷的 Laboratory of Ecological and Biological Interactions。
• Bertrand Dupont holds the honorary editorship and is attached to the University Hospital Necker for Sick Children in Paris.（Bertrand Dupont）担任荣誉主编，任职于巴黎的 University Hospital Necker for Sick Children。
• Twenty-nine editors and board members serve the journal from 13 countries or regions, with France supplying 16, Switzerland 2 and Argentina 1.29 位编辑与编委分布在 13 个国家或地区，其中法国 16 位，瑞士 2 位，阿根廷 1 位。
• The 26 editors include staff of the Institut Pasteur and of the Necker and Henri Mondor hospitals, together with researchers from Grenoble Alpes, Tours, Poitiers, Limoges and Lyon 1.26 位编辑的机构包括 Institut Pasteur、巴黎的 Necker 医院与 Henri Mondor 医院，也有格勒诺布尔-阿尔卑斯大学、里昂第一大学等校的研究者。
• Members from beyond France widen that spread, with posts in Switzerland, Belgium, Spain, Portugal, Argentina, Colombia, Morocco, Indonesia, Nigeria, India, the Czech Republic and South Africa.法国以外的成员进一步拉开分布，瑞士、比利时与西班牙都有编委，葡萄牙与阿根廷也有代表。名单再往远处延伸，哥伦比亚、摩洛哥与印度尼西亚各有任职，尼日利亚与印度有编委，捷克与南非同样在列。
• Review is single anonymized, so a referee learns who wrote the paper while the author never learns who assessed it.评审采用单盲，审稿人知道论文作者是谁，作者始终不知道评审人是谁。
• Every submission is first assessed by an editor for fit with the journal, and papers that pass go to at least two independent expert reviewers.每篇投稿先由编辑评估是否适合本刊，通过初评的稿件至少送两位独立专家评审。
• The editor carries the final decision, the journal states that this decision is final, and no paper is promised publication before the editorial board has ruled.最终决定由编辑作出，刊物声明该决定为终局，在编委会裁定之前不向任何稿件承诺发表。
• Editors step aside from papers they wrote themselves, from papers by family members or colleagues, and from work touching a product or service in which they hold an interest.编辑回避自己撰写的稿件，也回避亲属或同事撰写以及涉及本人利益的产品或服务的稿件。
• Such submissions still follow the usual procedure, and peer review is handled independently of the editor involved and of that editor's research group.这类稿件仍走常规流程，外审独立于相关编辑及其课题组。
• Authors may suggest reviewers with institutional email addresses, but not colleagues or co-authors from the past three years, and the list should span several countries.作者可以推荐审稿人并附机构邮箱，但不得推荐同事或近三年的合作者，名单也应跨越多个国家。
• Human studies must follow the Declaration of Helsinki, a clinical trial has to be registered in a public registry before the first patient is enrolled, and the registration number goes at the end of the abstract.人体研究须遵循赫尔辛基宣言，临床试验必须在首位患者入组前完成公共注册，注册号印在摘要末尾。
• Animal work follows the ARRIVE guidelines, and any study on plants, lichens or fungi must state that it complied with the Nagoya protocol.动物实验遵循 ARRIVE 指南，涉及植物、地衣或真菌的研究须声明遵守名古屋议定书。
• Use of generative AI in preparing a manuscript must be declared, in a section placed before the references.使用生成式 AI 工具辅助撰稿必须声明，声明段置于参考文献之前。
• Manuscripts go through Editorial Manager at editorialmanager.com/mycmed, the editorial office answers at mycmed@elsevier.com, and decisions and revision requests travel by email.稿件经 editorialmanager.com/mycmed 的 Editorial Manager 提交，编辑部邮箱（mycmed@elsevier.com）同样印在指南上，决定与修回通知一律通过邮件送达。